Showing 1 - 5 results of 5 for search 'Antonio Salar-Silvestre', query time: 0.03s
Refine Results
-
1
More is not always better, sometimes it is just more by Antonio Salar Silvestre
Published 2024-03-01
Article -
2
PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPH... by Antonio Salar Silvestre, Judith Trotman, Clementine Sarkozy, Yuqin Song, Laurie H. Sehn, Loretta J. Nastoupil, Wanhua Zhang, Pierre Fustier, Richard Delarue, Pier Luigi Zinzani
Published 2023-08-01
Article -
3
P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL) by Daniel Hodson, Geoffrey Shouse, Ho-Jin Shin, Antonio Salar Silvestre, Sabela Bobillo Varela, Vincent Ribrag, Nicol Macpherson, Raul Cordoba, Jin Seok Kim, John Radford, Stephanie Guidez, Alex F. Herrera, Franck Morschhauser, Dachelle Johnson, Macarena Izuzquiza, Nisha Sambamurthy, Alessandra Forcina, Gullu Gorgun, Robert Chen, Anas Younes, Michael Wang, Wong Seog Kim
Published 2023-08-01
Article -
4
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the... by Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Published 2021-06-01
Article -
5
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma by Lourdes Hontecillas-Prieto, Lourdes Hontecillas-Prieto, Lourdes Hontecillas-Prieto, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Víctor Sánchez-Margalet, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, Luis de la Cruz-Merino, Luis de la Cruz-Merino
Published 2024-02-01
Article